Synaptogenix, Inc. (NASDAQ:TAOX – Get Free Report)’s share price was down 11% during mid-day trading on Monday. The stock traded as low as $2.48 and last traded at $2.52. 118,688 shares traded hands during trading, a decline of 22% from the average daily volume of 151,668 shares. The stock had previously closed at $2.83.
Analyst Ratings Changes
A number of research firms recently issued reports on TAOX. Wall Street Zen cut shares of Synaptogenix from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.
Read Our Latest Research Report on TAOX
Synaptogenix Price Performance
The company has a fifty day moving average price of $3.81 and a two-hundred day moving average price of $4.24. The company has a market capitalization of $21.47 million, a P/E ratio of -0.69 and a beta of 1.81.
Synaptogenix (NASDAQ:TAOX – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.83) earnings per share (EPS) for the quarter. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%. The business had revenue of $0.09 million during the quarter.
About Synaptogenix
Synaptogenix, Inc is a biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. Its research has centered primarily on bryostatin-1, a drug candidate being investigated for its potential to improve synaptic function and memory.
The company has historically pursued treatments for conditions including Alzheimer’s disease and Fragile X syndrome. Its development programs have been research- and clinical-stage, with no indication that it operates a broad commercial product portfolio.
Synaptogenix was formerly known as Neurotrope, Inc and adopted its current name as part of a strategic focus on neuroscience-based therapeutics.
Further Reading
- Five stocks we like better than Synaptogenix
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
